Prognostic significance of hyperfibrinogenemia in patients with esophageal squamous cell carcinoma. 2017

Takashi Suzuki, and Hideaki Shimada, and Tatsuki Nanami, and Yoko Oshima, and Satoshi Yajima, and Naohiro Washizawa, and Hironori Kaneko
Department of Surgery, School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan.

BACKGROUND Preoperative hyperfibrinogenemia is associated with inflammatory mediators and a poor prognosis in several types of cancer. However, there is no published information on the monitoring of patients with preoperative hyperfibrinogenemia after surgery. The aim of the study reported here was to assess the clinicopathological and prognostic significance of plasma fibrinogen levels in patients with esophageal squamous cell carcinoma before and after surgical treatment. METHODS Plasma fibrinogen levels were analyzed before surgical treatment (endoscopic submucosal dissection and surgery) in 82 patients with esophageal squamous cell carcinoma. The clinicopathological significance of plasma fibrinogen levels and the relationship of plasma fibrinogen levels with several biomarkers were evaluated. The cutoff value for hyperfibrinogenemia was 321 mg/dl. Univariate and multivariate analysis using the Cox proportional hazards model were performed to evaluate the prognostic significance of plasma fibrinogen levels. The changing patterns of plasma fibrinogen were monitored after surgical treatment to evaluate prognostic impact. RESULTS Hyperfibrinogenemia was significantly associated with advanced pathological stage of cancer and high C-reactive protein levels. Plasma fibrinogen levels significantly decreased after surgical treatment in recurrence-free patients but did not decrease in patients with recurrence. The multivariate analysis indicated that preoperative hyperfibrinogenemia was an independent prognostic factor for poor survival (hazard ratio 1.005, 95% confidence interval 1.000-1.010; P = 0.039). CONCLUSIONS Preoperative hyperfibrinogenemia was associated with inflammatory mediators, tumor progression, and poor survival in patients with esophageal squamous cell carcinoma. The absence of a decrease in plasma fibrinogen levels after surgical treatment may indicate the possibility of tumor recurrence.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011517 Prothrombin Time Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS. Quick Test,Russell's Viper Venom Time,Thrombotest,Russell Viper Venom Time,Russells Viper Venom Time,Prothrombin Times,Test, Quick,Time, Prothrombin,Times, Prothrombin
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D004938 Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. Cancer of Esophagus,Esophageal Cancer,Cancer of the Esophagus,Esophagus Cancer,Esophagus Neoplasm,Neoplasms, Esophageal,Cancer, Esophageal,Cancer, Esophagus,Cancers, Esophageal,Cancers, Esophagus,Esophageal Cancers,Esophageal Neoplasm,Esophagus Cancers,Esophagus Neoplasms,Neoplasm, Esophageal,Neoplasm, Esophagus,Neoplasms, Esophagus
D005260 Female Females

Related Publications

Takashi Suzuki, and Hideaki Shimada, and Tatsuki Nanami, and Yoko Oshima, and Satoshi Yajima, and Naohiro Washizawa, and Hironori Kaneko
October 2013, Anticancer research,
Takashi Suzuki, and Hideaki Shimada, and Tatsuki Nanami, and Yoko Oshima, and Satoshi Yajima, and Naohiro Washizawa, and Hironori Kaneko
September 2015, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Takashi Suzuki, and Hideaki Shimada, and Tatsuki Nanami, and Yoko Oshima, and Satoshi Yajima, and Naohiro Washizawa, and Hironori Kaneko
July 2015, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus,
Takashi Suzuki, and Hideaki Shimada, and Tatsuki Nanami, and Yoko Oshima, and Satoshi Yajima, and Naohiro Washizawa, and Hironori Kaneko
June 2013, Archives of Iranian medicine,
Takashi Suzuki, and Hideaki Shimada, and Tatsuki Nanami, and Yoko Oshima, and Satoshi Yajima, and Naohiro Washizawa, and Hironori Kaneko
April 2003, Journal of the American College of Surgeons,
Takashi Suzuki, and Hideaki Shimada, and Tatsuki Nanami, and Yoko Oshima, and Satoshi Yajima, and Naohiro Washizawa, and Hironori Kaneko
January 2014, Therapeutics and clinical risk management,
Takashi Suzuki, and Hideaki Shimada, and Tatsuki Nanami, and Yoko Oshima, and Satoshi Yajima, and Naohiro Washizawa, and Hironori Kaneko
January 2012, Journal of surgical oncology,
Takashi Suzuki, and Hideaki Shimada, and Tatsuki Nanami, and Yoko Oshima, and Satoshi Yajima, and Naohiro Washizawa, and Hironori Kaneko
May 2016, Archives of medical research,
Takashi Suzuki, and Hideaki Shimada, and Tatsuki Nanami, and Yoko Oshima, and Satoshi Yajima, and Naohiro Washizawa, and Hironori Kaneko
July 2002, Surgery,
Takashi Suzuki, and Hideaki Shimada, and Tatsuki Nanami, and Yoko Oshima, and Satoshi Yajima, and Naohiro Washizawa, and Hironori Kaneko
April 2023, BMC cancer,
Copied contents to your clipboard!